Five things for pharma marketers to know: Friday, January 13, 2017

CVS to sell generic EpiPen; FDA finalizes biosimilar naming rules; Pfizer wants to make a deal

Klick Health's Elliot Langerman on the Power of Persuasion

Here are six global campaigns that make the case for persuasion.

Japanese drugmakers lead the way in digital innovation

Otsuka, Astellas, Takeda, and Daiichi Sankyo share a degree of adventurousness and forward-mindedness in the digital realm.

Day 3 at JP Morgan: The move toward big data requires drugmakers to ask questions

Day 3 at JP Morgan: The move toward big data requires drugmakers to ask questions

There are dozens of players, including leaders like IBM Watson Health and Verily as well as smaller concerns, lining up to sell pharma access to some sort of data solution.

Merck's Keytruda combo could edge out the competition

Merck's Keytruda combo could edge out the competition

Merck said the FDA accepted its submission of a Keytruda/chemotherapy combo drug and granted it Priority Review.

Physicians group urges metformin rather than new drugs

Physicians group urges metformin rather than new drugs

The American College of Physicians said the costs of some new diabetes drugs do not always mean added benefits for patients.





Jaimy Lee, MM&M's executive editor, talks with Sam Johnson, director of data science at Intouch Solutions, to talk about big data at MM&M's Big Data for Big Decisions event, held in December in New York City, in this sponsored video series.



GCI Health plants its flag in Philadelphia

GCI Health plants its flag in Philadelphia

The firm is sharing space in the City of Brotherly Love with healthcare media shop CMI.

Five things for pharma marketers to know: Thursday, January 12, 2017

Five things for pharma marketers to know: Thursday, January 12, 2017

Trump says pharma is "getting away with murder"; Senate majority votes to repeal ACA; IBM Watson Health and FDA to study blockchain technology

Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?

Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?

J&J's CEO may be right. Customers of all kinds are demanding change.

Five things for pharma marketers to know: Wednesday, January 11, 2017

Five things for pharma marketers to know: Wednesday, January 11, 2017

The FDA accepts Keytruda combo for review; Valeant offloads Dendreon and skincare brands; pharmacies feeling the squeeze from Express Scripts

Tonic Life promotes Stephanie DeViteri to MD

Tonic Life promotes Stephanie DeViteri to MD

DeViteri started in the newly created role this month.

Infographic: Can pharma give doctors what they want?

Infographic: Can pharma give doctors what they want?

Physicians do not like EHRs. That much is clear. But the vast majority have to use electronic record systems on a daily basis. What can pharma do to better give doctors what they want?

Day 1 at JP Morgan: Pricing is top of mind for pharma CEOs

Day 1 at JP Morgan: Pricing is top of mind for pharma CEOs

The questions being asked about how drugs are priced are weighing heavily on pharma leaders, and they know the issue is not going away.

Five things for pharma marketers to know: Tuesday, January 10, 2017

Five things for pharma marketers to know: Tuesday, January 10, 2017

Illumina and IBM enter DNA sequencing partnership; J&J to outline price increases in new report; Egalet's opioid Arymo ER gets FDA approval

Top 25 cardiovascular brands, 2015-2016

Top 25 cardiovascular brands, 2015-2016

The top-selling heart drug is Merck's Zetia, which is expected to bring in about $1.68 billion in sales in 2016.

For statin-intolerant patients, what's next?

For statin-intolerant patients, what's next?

Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.

When it comes to PCSK9s, payers resisted — and sales flopped

When it comes to PCSK9s, payers resisted — and sales flopped

The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?

Ex-Guidemark CEO Matt Brown hangs out new shingle, Brand Mettle

Ex-Guidemark CEO Matt Brown hangs out new shingle, Brand Mettle

The new agency will focus on marketing goods and services to people 50 years of age and older.

MMC's Diana Littman on waiting for a decision after a pitch

MMC's Diana Littman on waiting for a decision after a pitch

She says her experience in consumer brands helps her push healthcare clients to be more creative.

Five things for pharma marketers to know: Monday, January 9, 2017

Five things for pharma marketers to know: Monday, January 9, 2017

Takeda to acquire Ariad for $4.6 billion, Merck pairs with Incyte for Keytruda combo drug collaboration; Sanofi announces autoimmune research deal

Shark Tank's Herjavec shares his tips for innovation competitions

Shark Tank's Herjavec shares his tips for innovation competitions

When his mother suffered from ovarian cancer a decade ago, Robert Herjavec found himself frustrated by the quality of care she received.

Agency Spotlight

Featured Listings

LevLane

LevLane

Featured Work: Kennedy Health brings sophisticated healthcare to South Jersey, and we wanted this ...

OPINION

Healthcare Marketers: The Future is Personal

Email Newsletters